A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Days 1-3 of a 21-Day Cycle in Patients With Solid Tumors

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Days 1-3 of a 21-Day Cycle in Patients With Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Ispinesib (Primary)
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Granulomatosis; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Planned number of patients changed from 18 to 31 as reported by ClinicalTrials.gov record.
    • 20 Apr 2010 Actual end date (1 Feb 2010) added.as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top